司美格魯肽作為新型的人胰高血糖素樣肽-1受體激動(dòng)劑，在國內(nèi)用于2型糖尿病的治療，其獨(dú)特藥物特性賦予其在血糖控制、體質(zhì)量管理和胰島素抵抗改善等方面顯著效果。近年臨床研究進(jìn)一步揭示其在降低心血管事件、代謝相關(guān)脂肪性肝炎、癌癥免疫治療和神經(jīng)退行性疾病等領(lǐng)域的潛力。然而，應(yīng)用司美格魯肽也伴隨一些新風(fēng)險(xiǎn)，如膽囊疾病和延遲胃排空帶來的臨床隱憂。匯總最新研究成果，全面評估司美格魯肽在各領(lǐng)域的療效和安全性，旨在為其更廣泛的臨床應(yīng)用提供指導(dǎo)。

As a novel glucagon-like peptide-1 receptor agonist (GLP-1RA), semaglutide is utilized domestically for the treatment of type 2 diabetes mellitus (T2DM). Its unique pharmacological characteristics endow it with significant effects in blood glucose control, weight management, and improvement of insulin resistance. Recent clinical research further reveals its potential in reducing cardiovascular events, non-alcoholic fatty liver disease, cancer immunotherapy, and neurodegenerative diseases. However, the use of semaglutide is also accompanied by some new risks, such as concerns related to gallbladder diseases and delayed gastric emptying. This article summarizes the latest research findings, comprehensively assessing the efficacy and safety of semaglutide in various fields, with the aim of providing guidance for its broader clinical application.

R965.3